Intelligent Bio Solutions Stock Performance
| INBS Stock | USD 1.67 0.09 5.11% |
On a scale of 0 to 100, Intelligent Bio holds a performance score of 5. The company retains a Market Volatility (i.e., Beta) of 1.02, which attests to a somewhat significant risk relative to the market. Intelligent Bio returns are very sensitive to returns on the market. As the market goes up or down, Intelligent Bio is expected to follow. Please check Intelligent Bio's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Intelligent Bio's current trending patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Intelligent Bio Solutions are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental drivers, Intelligent Bio unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.5 M |
Intelligent |
Intelligent Bio Relative Risk vs. Return Landscape
If you would invest 144.00 in Intelligent Bio Solutions on December 26, 2024 and sell it today you would earn a total of 24.00 from holding Intelligent Bio Solutions or generate 16.67% return on investment over 90 days. Intelligent Bio Solutions is currently generating 0.4561% in daily expected returns and assumes 6.3993% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Intelligent, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Intelligent Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intelligent Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Intelligent Bio Solutions, and traders can use it to determine the average amount a Intelligent Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0713
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | INBS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.4 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.46 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Intelligent Bio is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Intelligent Bio by adding it to a well-diversified portfolio.
Intelligent Bio Fundamentals Growth
Intelligent Stock prices reflect investors' perceptions of the future prospects and financial health of Intelligent Bio, and Intelligent Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Intelligent Stock performance.
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (3.86) % | ||||
| Current Valuation | 12.7 M | ||||
| Shares Outstanding | 4.39 M | ||||
| Price To Book | 3.28 X | ||||
| Price To Sales | 4.72 X | ||||
| Revenue | 3.11 M | ||||
| EBITDA | (8.81 M) | ||||
| Cash And Equivalents | 8.28 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 871.44 K | ||||
| Book Value Per Share | 2.41 X | ||||
| Cash Flow From Operations | (9.57 M) | ||||
| Earnings Per Share | (2.30) X | ||||
| Total Asset | 13.78 M | ||||
| Retained Earnings | (51.96 M) | ||||
About Intelligent Bio Performance
Assessing Intelligent Bio's fundamental ratios provides investors with valuable insights into Intelligent Bio's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Intelligent Bio is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. Intelligent Bio operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.Things to note about Intelligent Bio Solutions performance evaluation
Checking the ongoing alerts about Intelligent Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Intelligent Bio Solutions help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Intelligent Bio had very high historical volatility over the last 90 days | |
| Intelligent Bio may become a speculative penny stock | |
| Intelligent Bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 3.11 M. Net Loss for the year was (10.19 M) with profit before overhead, payroll, taxes, and interest of 326.67 K. | |
| Intelligent Bio Solutions currently holds about 8.28 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56. | |
| Intelligent Bio has a frail financial position based on the latest SEC disclosures |
- Analyzing Intelligent Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Intelligent Bio's stock is overvalued or undervalued compared to its peers.
- Examining Intelligent Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Intelligent Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Intelligent Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Intelligent Bio's stock. These opinions can provide insight into Intelligent Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.